In Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, Zafren K, Hackett PH, Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness, WEM 21:147-155, an important aspect of classifying risk was omitted in Table 3 on page 149. We sincerely regret the error and submit the corrected Table 3.
Table 3Risk Categories for Acute Mountain Sickness
| Risk Category | Description |
|---|---|
| Low |
|
| Moderate |
|
| High |
|
AMS, Acute mountain sickness; HACE, High altitude cerebral edema; HAPE, High altitude pulmonary edema
Notes:
• Altitudes listed in the table refer to the altitude at which the person sleeps
• Ascent is assumed to start from elevations < 1200 m
• The risk categories described above pertain to unacclimatized individuals
Article info
Identification
Copyright
© 2010 Published by Elsevier Inc.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude IllnessWilderness & Environmental MedicineVol. 21Issue 2
- PreviewTo provide guidance to clinicians about best practices, the Wilderness Medical Society (WMS) convened an expert panel to develop evidence-based guidelines for the prevention and treatment of acute mountain sickness (AMS), high altitude cerebral edema (HACE), and high altitude pulmonary edema (HAPE). These guidelines present the main prophylactic and therapeutic modalities for each disorder and provide recommendations for their roles in disease management. Recommendations are graded based on the quality of supporting evidence and balance between the benefits and risks/burdens according to criteria put forth by the American College of Chest Physicians.
- Full-Text
- Preview
